Skip to main content
Article thumbnail
Location of Repository

Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors

By Divina G Brillante, Anthony J O’Sullivan and Laurence G Howes


The insulin resistance syndrome (INSR) is associated with increased cardiovascular risk, and affects up to 25% of the Australian population aged >20 years. Increased arterial stiffness has been proposed as a common pathway by which INSR leads to increased cardiovascular risk. We have reviewed the role of nitric oxide (NO) and angiotensin II receptors in the modulation of arterial stiffness in the setting of insulin resistance. There is emerging evidence that early stages of INSR may be characterized by increased basal nitric oxide activity and increased activity of non-NO vasodilators such as endothelial derived hyperpolarization factor (EDHF) which is manifest by reduced arterial stiffness. Depletion of NO or ineffectiveness of NO mediated vasodilator mechanisms associated with the progression of INSR to type 2 diabetes may result in increased arterial stiffness, which predicts the development of cardiovascular disease. Thus in the early stages of INSR, increased NO and EDHF activity may represent compensatory mechanisms to early vascular damage. The renin-angiotensin system is activated in diseased vascular beds, with up regulation of the two known angiotensin II receptors: the angiotensin II type 1 receptor (AT1R) and the angiotensin II type 2 receptor (AT2R). Increased AT1R mediated activity in the vasculature is central to the development of increased arterial stiffness and is enhanced in INSR states. AT2R activity is increased in early in INSR and may contribute to the apparent increase in basal NO activity. AT1R blockade may therefore be valuable treatment for early INSR as antagonism of AT1 receptors would allow angiotensin II to act unopposed at AT2 receptors

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. Angiotensin II and the endothelium: diverse signals and effects.
  2. Angiotensin II AT2 receptor subtype: An uprising frontier in cardiovascular disease?
  3. (1999). Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells: involvement of the AT1 receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol.
  4. Angiotensin II stimulates endothelial NO synthase phosphorylation in thoracic aorta of mice with abdominal aortic banding via type 2 receptor. Hypertension.
  5. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
  6. (2001). Angiotensin II type 2 receptors: Signalling and pathophysiological role. Curr Opin Nephrol Hyperten.
  7. Angiotensin Type 2 Receptor in resistance arteries of type 2 diabetic hypertensive patients.
  8. Arterial disease/ hypertension/ angiotensin system: non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: The ARIC Study.
  9. Arterial elasticity in cardiovascular disease: focus on hypertension, metabolic syndrome and diabetes. Adv Cardio.
  10. (2001). Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens.
  11. (2008). Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome. Clin Sci.
  12. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease.
  13. Arterial stiffness increases with deteriorating glucose tolerance status: The Hoorn Study.
  14. (2006). Basal production of nitric oxide (NO) and non-NO vasodilators in the forearm circulation in type 2 diabetes: Associations with blood pressure and HDL cholesterol. Diabet Res Clin Pract.
  15. Clustered features of the metabolic syndrome and the risk for increased aortic pulse wave velocity in middle-aged Japanese men.
  16. (2008). Does compensatory nitric oxide and angiotensin II receptor activity reduce arterial stiffness in early-stage insulin resistance? Clin Sci.
  17. (2006). Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with pre-diabetes or non-diabetic metabolic syndrome.
  18. (2005). Effects of intravenous PD123319 on haemodynamic and arterial stiffness indices in healthy volunteers. J Renin Angiotens Aldo Syst.
  19. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
  20. (1996). Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin dependent diabetes. Br Med J.
  21. (2008). Evidence for functional expression of vascular AT2 receptors in patients with insulin resistance. Diabet Obes Metab.
  22. Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response.
  23. Features of endothelial dysfunction in early diabetic nephropathy.
  24. (1997). Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients.
  25. (2003). Functional interplay between angiotensin II and nitric oxide: cyclic GMP as key mediator. Arterioscler Thromb Vasc Biol.
  26. Impact of aortic stiffness on survival in end-stage renal disease.
  27. (1996). Impaired radial artery compliance in normotensive subjects with familial hypercholesterolaemia.
  28. (1999). In vivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabet Care.
  29. Increased basal levels of plasma nitric oxide in type 2 diabetic subjects. Relationship to microvascular complications.
  30. Increased pulse wave velocity is not associated with elevated augmentation index inpatients with diabetes.
  31. (1996). Increased stiffness of the aorta in children and adolescents with insulin-dependent diabetes mellitus. Ultrasound Med Biol.
  32. (1993). Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci.
  33. (2000). International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev.
  34. (1993). Isobaric compliance of the radial artery is increased in patients with essential hypertension. J Hypertens.
  35. (2002). Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in type II diabetes. Clin Sci.
  36. (2005). Metabolic syndrome in relation to structure and function of large arteries: a predominant effect of blood pressure: a report from the SU.VI.MAX. Vascular Study. Am J Hypertens.
  37. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology.
  38. Nitric oxide regulates local arterial distensibility in vivo.
  39. (2000). Nitric oxide: A physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand.
  40. (2005). pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol.
  41. (1999). Photoplethysmographic assessment of pulse wave refl ection: Blunted response to endothelium-dependent beta2-adrenergic vasodilatation in type 2 diabetes mellitus.
  42. Pressor factors and responsiveness in hypertension accompanying diabetes mellitus.
  43. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects.
  44. (2007). Pulse wave velocity reference values in healthy adults aged 26–75 years. Clin Physiol Funct Imag.
  45. (1995). Radial artery compliance in young, obese, normotensive subjects. Hypertension.
  46. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
  47. (2004). Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. Diabet Res Clin Pract.
  48. (2006). Review: The effects of lipid lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients. Diabet Obes Metabol.
  49. (2007). Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats. Diabet Res Clin Pract.
  50. (1999). Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension.
  51. Study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
  52. (1999). Systemic arterial compliance is reduced in young patients with IDDM.
  53. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nature Rev Drug Discov.
  54. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events.
  55. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
  56. (1996). The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med.
  57. Time course of endothelial dysfunction in diabetes mellitus.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.